Can pre-treatment inflammatory biomarker levels predict the response of tocilizumab therapy in COVID-19 patients?

Q4 Medicine

Gulhane Medical Journal Pub Date : 2023-12-01 DOI:10.4274/gulhane.galenos.2023.04834

Mehmet Nur Kaya, D. Tecer, M. Çınar, F. Bıçakcı, Emre Tekgöz, S. Çolak, S. Yılmaz

引用次数: 0

查看原文本刊更多论文

治疗前的炎症生物标志物水平能否预测 COVID-19 患者对托珠单抗治疗的反应？

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gulhane Medical Journal Medicine-Medicine (all)

CiteScore

0.40

自引率

0.00%

发文量

期刊介绍： History of the Gulhane Medical Journal goes back beyond the second half of the nineteenth century. "Ceride-i Tıbbiye-yi Askeriye" is the first journal published by the Turkish military medical community between 1871 and 1931. This journal was published as "Askeri Tıp Mecmuası", "Askeri Sıhhiye Mecmuası","Askeri Sıhhiye Dergisi" and "GATA Bülteni" between 1921 to 1931, 1931 to 1949, 1949 to 1956 and 1956 to 1998, respectively. The journal is currently being published as "Gülhane Tıp Dergisi" ("Gulhane Medical Journal") since the September 1998 issue.